MA44862A - Formulations de fulvestrant et méthodes d'utilisation de celles-ci - Google Patents
Formulations de fulvestrant et méthodes d'utilisation de celles-ciInfo
- Publication number
- MA44862A MA44862A MA044862A MA44862A MA44862A MA 44862 A MA44862 A MA 44862A MA 044862 A MA044862 A MA 044862A MA 44862 A MA44862 A MA 44862A MA 44862 A MA44862 A MA 44862A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- fulvestrant formulations
- fulvestrant
- formulations
- Prior art date
Links
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title 1
- 229960002258 fulvestrant Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332842P | 2016-05-06 | 2016-05-06 | |
| US201662420555P | 2016-11-10 | 2016-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44862A true MA44862A (fr) | 2019-03-13 |
Family
ID=58709642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044862A MA44862A (fr) | 2016-05-06 | 2017-05-05 | Formulations de fulvestrant et méthodes d'utilisation de celles-ci |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190134059A1 (fr) |
| EP (1) | EP3452011A1 (fr) |
| JP (3) | JP2019516789A (fr) |
| KR (1) | KR102438425B1 (fr) |
| CN (1) | CN109310621A (fr) |
| AU (2) | AU2017261321B2 (fr) |
| CA (1) | CA3022834A1 (fr) |
| CO (1) | CO2018013257A2 (fr) |
| IL (2) | IL285928B2 (fr) |
| MA (1) | MA44862A (fr) |
| MX (2) | MX2018013414A (fr) |
| MY (1) | MY205661A (fr) |
| UA (1) | UA125514C2 (fr) |
| WO (1) | WO2017193048A1 (fr) |
| ZA (1) | ZA201807031B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| CN111479556B (zh) * | 2017-11-08 | 2023-09-01 | 伊格尔制药公司 | 氟维司群制剂及其使用方法 |
| CN113260353B (zh) * | 2019-12-11 | 2024-11-29 | 上海云晟研新生物科技有限公司 | 氟维司群药物组合物、其制备方法及应用 |
| CN113694017B (zh) * | 2020-05-11 | 2024-04-02 | 鲁南制药集团股份有限公司 | 一种氟维司群注射制剂及其制备方法 |
| WO2022100750A1 (fr) * | 2020-11-16 | 2022-05-19 | 北京厚燊维康科技有限责任公司 | Préparation disponible pour une thérapie ou un diagnostic photodynamique |
| CN120284882A (zh) * | 2020-12-10 | 2025-07-11 | 上海云晟研新生物科技有限公司 | 氟维司群药物组合物、其制备方法及应用 |
| JP2024545690A (ja) * | 2021-12-20 | 2024-12-10 | サムヤン、ホールディングス、コーポレーション | 溶解度が改善されたフルベストラントの医薬組成物及びその製造方法 |
| KR20240105964A (ko) * | 2022-12-29 | 2024-07-08 | 주식회사 삼양홀딩스 | 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| EP1282401A2 (fr) | 2000-05-15 | 2003-02-12 | PHARMACIA & UPJOHN S.p.A. | Suspension steroidique stabilisee |
| US6495534B2 (en) | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| GB0116619D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| HUP0400115A3 (en) * | 2001-07-07 | 2005-11-28 | Astrazeneca Ab | Pharmaceutical composition for the intramuscular administration of fulvestrant |
| JP2003298516A (ja) | 2002-03-29 | 2003-10-17 | Fujitsu Ltd | 波長分散補償装置 |
| PL1778187T3 (pl) | 2004-08-04 | 2012-09-28 | Camurus Ab | Kompozycje tworzące nielamelarne dyspersje |
| EP2484344B1 (fr) | 2005-05-09 | 2016-02-10 | Biosphere Medical, S.A. | Compositions et procédés pour utiliser des microsphères et des agents de contraste non ioniques |
| WO2007069272A2 (fr) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Nouvelles compositions ameliorees pour la therapie du cancer |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN101108168B (zh) * | 2007-08-03 | 2010-12-08 | 西安力邦医药科技有限责任公司 | 一种氟维司群缓释微球的制备方法 |
| US9254268B2 (en) | 2007-09-25 | 2016-02-09 | Solubest Ltd. | Compositions comprising lipophilic active compounds and method for their preparation |
| CA2716576A1 (fr) | 2008-03-07 | 2009-09-11 | Nageswara R. Palepu | Formulations de fulvestrant |
| TW201016220A (en) * | 2008-10-31 | 2010-05-01 | Scinopharm Taiwan Ltd | Micronization form of 7α-[9-(4,4,5,5,5-pentafluoropentylsufinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol and process for the preparation thereof |
| KR20120052937A (ko) | 2009-06-18 | 2012-05-24 | 아보트 러보러터리즈 | 안정한 나노입자형 약물 현탁액 |
| WO2011022861A1 (fr) | 2009-08-31 | 2011-03-03 | 西安力邦医药科技有限责任公司 | Nanosphère/microsphère de fulvestrant, procédé de préparation et utilisation associés |
| WO2011011978A1 (fr) * | 2009-07-31 | 2011-02-03 | 西安力邦医药科技有限责任公司 | Vecteur de médicament nanosphérique ou microsphérique, procédé de préparation, composition et utilisation de celui-ci |
| WO2012021791A2 (fr) | 2010-08-13 | 2012-02-16 | Scidose Llc | Formulation aqueuse à stabilité améliorée |
| EP2616078B1 (fr) * | 2010-09-16 | 2019-12-25 | Shimoda Biotech (Pty) Ltd | Compositions à base de fulvestrant, et procédés d'utilisation |
| EP2468258A1 (fr) | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Procédé de préparation d'une composition pharmaceutique comportant un ingrédient actif pharmaceutiquement faiblement soluble |
| CN103429267B (zh) | 2011-01-09 | 2016-05-04 | Anp科技公司 | 疏水分子诱导的支化聚合物集合体及其用途 |
| CA2836831C (fr) * | 2011-05-20 | 2015-06-02 | Capital, Business Y Gestion De Finanzas S.L. | Composition pharmaceutique |
| CN102915088A (zh) | 2011-08-03 | 2013-02-06 | 鸿富锦精密工业(深圳)有限公司 | 资料存储器固定装置 |
| US11179468B2 (en) * | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
| CA2869377C (fr) | 2012-04-09 | 2022-11-08 | Scidose, Llc | Formulations de fulvestrant |
| NZ702244A (en) | 2012-06-08 | 2017-06-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| CN104337761B (zh) * | 2013-08-07 | 2019-03-26 | 江苏豪森药业集团有限公司 | 氟维司群药物组合物 |
| JP2016529308A (ja) * | 2013-09-06 | 2016-09-23 | サラー ウッディン アハメド, | フルベストラント組成物 |
| US20160287601A1 (en) * | 2013-10-03 | 2016-10-06 | Millennium Pharmaceuticals, Inc. | Enhanced treatment regimens using pi3k inhibitors |
| HUP1300646A2 (en) | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| PT107433B (pt) | 2014-01-28 | 2018-12-04 | Hovione Farm S A | Processo de redução e controlo do tamanho de partícula |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| JP6235755B2 (ja) | 2014-07-02 | 2017-11-22 | ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク | 高いカーゴ対サーファクタント比を有するサーファクタント除去ミセル組成物 |
| WO2015018380A2 (fr) | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Nanoparticules thérapeutiques et leurs procédés de préparation |
-
2017
- 2017-05-04 IL IL285928A patent/IL285928B2/en unknown
- 2017-05-05 MX MX2018013414A patent/MX2018013414A/es unknown
- 2017-05-05 MY MYPI2018703903A patent/MY205661A/en unknown
- 2017-05-05 KR KR1020187034942A patent/KR102438425B1/ko active Active
- 2017-05-05 JP JP2019510578A patent/JP2019516789A/ja active Pending
- 2017-05-05 AU AU2017261321A patent/AU2017261321B2/en active Active
- 2017-05-05 MA MA044862A patent/MA44862A/fr unknown
- 2017-05-05 UA UAA201812019A patent/UA125514C2/uk unknown
- 2017-05-05 US US16/099,265 patent/US20190134059A1/en not_active Abandoned
- 2017-05-05 WO PCT/US2017/031376 patent/WO2017193048A1/fr not_active Ceased
- 2017-05-05 EP EP17723902.7A patent/EP3452011A1/fr active Pending
- 2017-05-05 CN CN201780027809.5A patent/CN109310621A/zh active Pending
- 2017-05-05 CA CA3022834A patent/CA3022834A1/fr active Pending
-
2018
- 2018-10-18 IL IL262465A patent/IL262465A/en unknown
- 2018-10-22 ZA ZA2018/07031A patent/ZA201807031B/en unknown
- 2018-11-01 MX MX2022013199A patent/MX2022013199A/es unknown
- 2018-12-06 CO CONC2018/0013257A patent/CO2018013257A2/es unknown
-
2021
- 2021-07-19 JP JP2021118471A patent/JP7312523B2/ja active Active
- 2021-07-19 US US17/379,534 patent/US12370199B2/en active Active
-
2023
- 2023-05-26 JP JP2023086732A patent/JP2023109959A/ja active Pending
- 2023-05-31 AU AU2023203392A patent/AU2023203392A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102438425B1 (ko) | 2022-09-01 |
| KR20190005183A (ko) | 2019-01-15 |
| EP3452011A1 (fr) | 2019-03-13 |
| NZ747911A (en) | 2025-03-28 |
| US20210346396A1 (en) | 2021-11-11 |
| JP2023109959A (ja) | 2023-08-08 |
| US12370199B2 (en) | 2025-07-29 |
| MY205661A (en) | 2024-11-04 |
| AU2017261321A1 (en) | 2018-11-15 |
| ZA201807031B (en) | 2023-10-25 |
| US20190134059A1 (en) | 2019-05-09 |
| UA125514C2 (uk) | 2022-04-13 |
| BR112018072768A2 (pt) | 2019-02-19 |
| AU2023203392A1 (en) | 2023-06-29 |
| IL262465A (en) | 2018-12-31 |
| IL285928A (en) | 2021-10-31 |
| CA3022834A1 (fr) | 2017-11-09 |
| JP2019516789A (ja) | 2019-06-20 |
| RU2018142068A (ru) | 2020-06-08 |
| IL285928B2 (en) | 2025-06-01 |
| JP2021169510A (ja) | 2021-10-28 |
| MX2018013414A (es) | 2019-06-06 |
| JP7312523B2 (ja) | 2023-07-21 |
| AU2017261321B2 (en) | 2023-03-09 |
| WO2017193048A1 (fr) | 2017-11-09 |
| IL285928B1 (en) | 2025-02-01 |
| RU2018142068A3 (fr) | 2020-09-17 |
| CN109310621A (zh) | 2019-02-05 |
| MX2022013199A (es) | 2022-12-13 |
| CO2018013257A2 (es) | 2018-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3402549A4 (fr) | Compositions pour micro-aiguilles et méthodes d'utilisation de celles-ci | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| EP3429591A4 (fr) | Inhibiteurs substitués de ménine-mll et méthodes d'utilisation | |
| EP3694529A4 (fr) | Protéines trispécifiques et méthodes d'utilisation | |
| MA49403A (fr) | Compositions de pde5 et méthodes d'immunothérapie | |
| MA48579A (fr) | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci | |
| MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
| MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
| EP3383430A4 (fr) | Anticorps et leurs méthodes d'utilisation | |
| MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
| EP3373969A4 (fr) | Composés interagissant avec le glycane et méthodes d'utilisation | |
| EP3328363A4 (fr) | Compositions et méthodes d'immunomodulation | |
| MA44862A (fr) | Formulations de fulvestrant et méthodes d'utilisation de celles-ci | |
| EP3319611A4 (fr) | Oxystérols et leurs méthodes d'utilisation | |
| EP3393382A4 (fr) | Couteau ophtalmique et méthodes d'utilisation | |
| MA48595A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
| EP3383917A4 (fr) | Nouveaux anticorps anti-claudine et méthodes d'utilisation | |
| EP3474857A4 (fr) | Compositions et méthodes de libération d'agents thérapeutiques | |
| MA44526A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| EP3525583A4 (fr) | Anticorps anti-c1s et leurs méthodes d'utilisation | |
| MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
| EP3551209A4 (fr) | Fusions d'insuline-fc et méthodes d'utilisation | |
| EP3728323A4 (fr) | Anticorps anti-fzd et méthodes d'utilisation | |
| EP3684819A4 (fr) | Anticorps anti-ykl40 et méthodes d'utilisation | |
| MA43282A (fr) | Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées |